Healthcare / Drug Manufacturers - Specialty & GenericTokyo
$2221.00
-61.00 (-2.67%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-221.0M · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
45/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$58.0B
P/E
22.5x
↑EV/EBITDA
9.4x
↓ROE
6.4%
↑Gross Margin
40.2%
↓Debt/Equity
0.66
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+13.4%
FCF CAGR
—
FCF margin
3.8%
FCF / Net income
0.65x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $51.68B · net income $3.00B · FCF $1.95B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $51.68B | $51.68B | $46.14B | $40.89B | $35.43B |
| Net Income | $3.00B | $3.00B | $6.15B | $3.44B | $2.70B |
| EBITDA | $8.29B | $8.29B | $12.15B | $7.53B | $6.54B |
| EPS | 122.94 | 122.94 | 252.85 | 141.37 | 111.01 |
| Gross Margin | 40.2% | 40.2% | 38.7% | 40.4% | 41.1% |
| Operating Margin | 9.7% | 9.7% | 8.4% | 9.4% | 10.7% |
| Net Margin | 5.8% | 5.8% | 13.3% | 8.4% | 7.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.66 | 0.66 | 0.64 | 0.70 | 0.69 |
| Current Ratio | 1.68 | 1.68 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.95B | $1.95B | $-221.0M | $-1.98B | $-13.08B |
| Returns | |||||
| ROE | 6.4% | 6.4% | 13.5% | 8.3% | 7.5% |
| Valuation | |||||
| P/E | 22.48 | 22.48 | 5.30 | 8.01 | 9.31 |
| EV/EBITDA | 9.39 | 9.39 | 4.71 | 7.19 | 7.05 |
| P/B | 1.16 | 1.16 | 0.71 | 0.67 | 0.70 |
| Growth & Yield | |||||
| Revenue Growth | 12.0% | 12.0% | 12.8% | 15.4% | — |
| EPS Growth | -51.4% | -51.4% | 78.9% | 27.3% | — |
| Dividend Yield | 2.1% | 2.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
17.0%
EPS terminal req.
$197.08
Spread vs growth
-68.4%
5Y implied EPS CAGR
14.2%
EPS terminal req.
$238.46
Spread vs growth
-65.5%
10Y implied EPS CAGR
12.1%
EPS terminal req.
$384.05
Spread vs growth
-63.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+75.0%
Start / end P/E
5.1x → 18.1x
EPS bridge
252.85 → 122.94
Residual
-131.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.